|
Market Closed -
Euronext Paris
16:55:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 157.60 EUR | +1.16% |
|
+4.23% | +32.44% |
| 10-22 | Ipsen: Better-than-expected Q3 overshadowed by 2027 Somatuline erosion and arbitration risk |  |
| 10-22 | Ipsen S.A. Upgrades Financial Guidance for the Full-Year 2026 | CI |
Business description: Ipsen
- oncology (69.2%);
- neuroscience (20.3%);
- rare diseases (10.5%).
At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.
Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Number of employees: 5,535
Sales by Activity: Ipsen
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Specialty Care | 2.75B | 3.16B | 3.31B | 3.57B | 3.93B |
Consumer Healthcare | 250M | - | - | - | - |
Geographical breakdown of sales: Ipsen
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
United States | - | - | - | - | 1.21B |
Europe | - | 1.24B | 1.26B | 1.34B | 1.17B |
Rest of World | - | 756M | 829M | 897M | 924M |
France | 314M | - | - | - | 293M |
North America | 916M | 1.03B | 1.04B | 1.17B | 80.3M |
Eastern Europe | 261M | - | - | - | - |
Other Rest of The World | 260M | - | - | - | - |
Asia | 252M | - | - | - | - |
Others Europe | 295M | - | - | - | - |
U.K. | 116M | - | - | - | - |
Germany | 199M | - | - | - | - |
Italy | 130M | - | - | - | - |
Spain | 125M | - | - | - | - |
Executive Committee: Ipsen
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 59 | 30/06/2020 |
| Chief Executive Officer | 57 | 31/12/2019 | |
Pierrick Lefranc
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Tech/Sci/R&D Officer | 59 | 21/09/2023 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 52 | 04/05/2023 |
Composition of the Board of Directors: Ipsen
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 29/08/2005 |
| Chairman | 68 | 21/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 31/05/2012 |
| Director/Board Member | 57 | 31/05/2020 | |
Michèle Ollier
BRD | Director/Board Member | 68 | 26/05/2015 |
Margaret Liu
BRD | Director/Board Member | 69 | 06/06/2017 |
Piet Wigerinck
BRD | Director/Board Member | 60 | 30/04/2018 |
David Loew
BRD | Director/Board Member | 59 | 30/06/2020 |
| Director/Board Member | 47 | 05/11/2020 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Company details: Ipsen
Group companies: Ipsen
| Name | Category and Sector |
|---|---|
Socapharma SAS | |
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.16% | +4.23% | +29.39% | +41.35% | 14.43B | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +1.99% | +5.73% | +44.86% | +80.24% | 427.64B | |
| Weighted average by Cap. | +2.00% | +6.59% | +50.44% | +100.24% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPN Stock
- Company Ipsen
Select your edition
All financial news and data tailored to specific country editions
